Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Abstract: The present disclosure relates to a molecular marker of the IGF2BP1 gene related to a chicken body size trait and the use thereof, and a genetic improvement method. In the present disclosure, it is found by means of gene association analysis that a deletion mutation in a promoter region of the IGF2BP1 gene of chicken is significantly associated with the chicken body size trait.

Abstract: The present disclosure provides a series battery pack capacity on-line monitoring and charging/discharging dual-state equalization circuit and method. The series battery pack capacity on-line monitoring and charging/discharging dual-state equalization circuit includes a storage battery pack, a gating switch array, a power dissipation loop, a polarity matching switch array, an isolated DC/DC converter, a bipolar differential battery voltage measurement circuit, a micro controller unit, a charging/discharging current detection loop, and a switch circuit unit. According to the present disclosure, each series battery of the storage battery pack can be separately charged and discharged by controlling the gating switch array, the storage battery pack capacity can be detected on line, bypass discharge and parallel supplement can be carried out on the series batteries with high or low relative state of charge in two states of charging and discharging, and the power of each series battery can be efficiently equalized.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Abstract: The present application relates to an antigen-binding protein and use thereof, wherein the antigen-binding protein comprises a VH and a VL, wherein the VH comprises an HCDR1, an HCDR2 and an HCDR3, wherein the HCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 10, the HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 12, the HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 14; and the VL comprises an LCDR1, an LCDR2 and an LCDR3, wherein the LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 2, the LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 4, and the LCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 6. The present application also relates to a pharmaceutical composition comprising the antigen-binding protein and use thereof for the treatment of a cancer.

Abstract: The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising an exogenous TCR and a switch receptor. Gene edited modified cells are also provided, such that the expression of one or more of an endogenous T-cell receptor gene (e.g., TRAC, TRBC) or an endogenous immune checkpoint gene (e.g., PD-1 or TIM-3) is downregulated.

Abstract: Disclosed herein are anti-mesothelin antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-mesothelin antibodies and antigen-binding fragments (“mesothelin CARs”) and genetically modified immune effector cells having such mesothelin CARs. Polynucleotides encoding the anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. Compositions comprising anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. The present disclosure also relates to uses of the anti-mesothelin antibodies and antigen-binding fragments and genetically modified immune effector cells having such mesothelin CARs in cancer treatment.

Abstract: A fully automated bead filler production line system and a fully automated bead filler molding and attaching method, implementing highly efficient production of bead filler in order to solve the problem in traditional production lines of large occupied area and low efficiency. To achieve said goal, the solution is to provide a fully automated bead filler production line system, comprising: a bead filler molding processing section, a functional auxiliary section, a filler and bead molding processing section, and automated material flow sections. The bead filler molding processing section, the functional auxiliary section, and the filler and bead molding processing section are sequentially linked, and two material flow sections are provided, on either side of the filler and bead molding processing system respectively.

Abstract: Disclosed herein are fusion proteins having a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) by binding to an activation receptor of the APC, and a second domain that activates an immune effector cell (e.g., a T cell) by targeting a co-stimulatory signaling pathway of the immune effector cell, as well as polynucleotides that encode such fusion proteins. Disclosed herein are also genetically engineered immune effector cells expressing such fusion protein, methods of their production, and their uses in treatment of diseases such as cancers.

Abstract: Disclosed herein are anti-BCMA antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-BCMA antibodies and antigen-binding fragments (“BCMA CARs”) and genetically modified immune effector cells having such BCMA CARs. Polynucleotides encoding the anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. Compositions comprising anti-BCMA antibodies and antigen-binding fragments and BCMA CARs are also provided herein. The present disclosure also relates to use of the anti-BCMA antibodies and antigen-binding fragments and genetically modified immune effector cells having such BCMA CARs in cancer treatment.

Abstract: The present invention includes a method for expanding a population of electroporated T cells. The method includes electroporating a population of cells comprising T cells with mRNA encoding a chimeric membrane protein comprising an antigen binding domain to a molecule and an intracellular domain of a co-stimulatory molecule, wherein the cultured T cells expand at least 10 fold. The invention further includes an expanded population of T cells, compositions comprising the cells and methods of treatment.

Abstract: The disclosure provides a method for monitoring abnormal sensors during fabrication of a semiconductor structure, an electronic device and storage medium. The method includes: measurement data of a wafer passing through different measurement sites are acquired; a plurality of measurement data included in each measurement site are input to a first classifier to select a first plurality of measurement sites; a plurality of measurement data corresponding to the first plurality of selected measurement sites are input to second and third classifiers to select a second plurality of measurement sites; the measurement data corresponding to the plurality of measurement sites are input to the first, second and third classifiers respectively, to select a plurality of target sensors; and the score of each target sensor group is obtained, and a plurality of target sensors in the target sensor group with the highest score are defined as abnormal sensors.

Abstract: A state monitoring method, a state monitoring apparatus and a state monitoring system for a developing device are provided. After image information is obtained through the acquired video information of the developing device, it is determined by an analysis unit whether the image information includes nozzle anomaly information, and alarm information is issued after the nozzle anomaly information is determined. Moreover, similarity between the image information that does not include the nozzle anomaly information and second preset nozzle anomaly information is compared, and the nozzle information is stored in the analysis unit in a case that the similarity between the image information and the second preset nozzle anomaly information is greater than a first threshold.

Abstract: Embodiments of this application disclose a method and a device for detecting network reliability. The method includes: A detection apparatus obtains a first quantity of data packets included in a first packet sent by a first network node to a second network node. The detection apparatus obtains first feedback information sent by the second network node, where the first feedback information includes a second quantity of data packets included in the first packet received by the second network node. The detection apparatus calculates communication service availability of a network channel from the first network node to the second network node based on at least one of the first quantity or the second quantity. Embodiments of this application can quickly and accurately detect and evaluate the network reliability.

Abstract: Disclosed herein are fusion proteins having a first domain that activates an antigen-presenting cell (APC) (e.g., a dendritic cell) by binding to an activation receptor of the APC, and a second domain that activates an immune effector cell (e.g., a T cell) by targeting a co-stimulatory signaling pathway of the immune effector cell, as well as polynucleotides that encode such fusion proteins. Disclosed herein are also genetically engineered immune effector cells expressing such fusion protein, methods of their production, and their uses in treatment of diseases such as cancers.

Abstract: A video encoding method is provided in the present invention. The method includes: determining a range of interest ROI in an ith frame, wherein the ROI comprises at least one ROI macroblock; extracting characteristic information of the at least one ROI macroblock, wherein the characteristic information comprises location information and type information of the at least one ROI macroblock; determining a quantization parameter QP corresponding to each of the at least one ROI macroblock; encoding the characteristic information of the at least one ROI macroblock according to the determined QP corresponding to each ROI macroblock, to obtain an ROI characteristic stream of the ith frame; and adding, to a video stream of the ith frame, the QP corresponding to each ROI macroblock and the ROI characteristic stream of the ith frame, to perform sending, wherein the video stream of the ith frame is obtained by encoding the ROI and a non-ROI comprised in the ith frame.

Abstract: The present disclosure provides modified immune cells or precursors thereof (e.g., gene edited modified T cells) comprising an exogenous T cell receptor (TCR) and/or a chimeric antigen receptor (CAR) having specificity for a target antigen, and an insertion and/or deletion in an endogenous gene locus encoding DNMT3A. Compositions and methods of treatment are also provided.

Abstract: The present invention includes a method for expanding a population of electroporated T cells. The method includes electroporating a population of cells comprising T cells with mRNA encoding a chimeric membrane protein comprising an antigen binding domain to a molecule and an intracellular domain of a co-stimulatory molecule, wherein the cultured T cells expand at least 10 fold. The invention further includes an expanded population of T cells, compositions comprising the cells and methods of treatment.